Molecular Markers for Progression of Pulmonary Fibrosis in Systemic Sclerosis

系统性硬化症肺纤维化进展的分子标志物

• 批准号: 8165452
• 负责人: Shervin Assassi
• 金额: $ 12.33万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-15 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8165452
• 关键词: Academic Medical Centers; Address; Applications Grants; Appointment; Area; Arthritis; Autoimmunity; Award; Bioethics; Bioinformatics; Biological Assay; Biological Markers; Biometry; Biostatistics Core; Blood Cells; Blood specimen; Cessation of life; Clinic; Clinical; Clinical Data; Clinical Research; Clinical Sciences; Clinical Trials Design; Collaborations; Complement; Complication; Connective Tissue Diseases; DNA Microarray Chip; Data; Data Analyses; Death Rate; Development; Development Plans; Disease; Disease Progression; Early Diagnosis; Educational Curriculum; Environment; Epidemiology; Evidence Based Medicine; Fibrosis; Funding; Future; Gene Expression; Gene Expression Profile; Gene Expression Profiling; Genetic; Genomics; Goals; Grant; Health Sciences; Immune; Indolent; Institution; Interferons; Interstitial Lung Diseases; Knowledge; Laboratories; Lead; Lung; Lymphocyte; Master' s Degree; Measurement; Mentored Clinical Scientist Development Program; Mentors; Mentorship; Methodology; Microarray Analysis; Modality; Modeling; Molecular; Molecular Profiling; Monitor; Morbidity - disease rate; Outcome; Outcome Study; Patients; Pattern; Peer Review; Predictive Value; Principal Investigator; Progressive Disease; Prospective Studies; Proteomics; Publications; Publishing; Pulmonary Fibrosis; RNA; Research; Research Design; Research Infrastructure; Research Personnel; Research Project Grants; Research Training; Respiratory Failure; Rheum; Rheumatism; Rheumatology; SECTM1 gene; Sampling; Scientist; Scleroderma; Serum; Skin; Subgroup; Systemic Scleroderma; Technology; Texas; Therapeutic; Tissues; Training; Transcript; Translational Research; United States National Institutes of Health; Universities; Whole Blood; Work; Writing; base; career; career development; chemokine; clinical care; cohort; design; experience; high risk; improved; molecular marker; monocyte; mortality; novel; peripheral blood; professor; programs; prospective; pulmonary function; success

DESCRIPTION (provided by applicant): Title: Molecular Markers for Progression of Pulmonary Fibrosis in Systemic Sclerosis Candidate: Dr. Assassi is an Assistant Professor in the Division of Rheumatology and in the Center for Clinical Research and Evidence Based Medicine. He has recently completed a Master's Degree Program in Clinical Research. He was selected as one of just two CCTS-KL2 (K12) Scholars in 2009 at the University of Texas-Health Science Center at Houston (UTHSC-H). Dr. Maureen D. Mayes (primary mentor) and Dr. Filemon K. Tan (co-mentor) are his mentors in the ongoing KL2 Award. Under their guidance, the candidate has published the largest gene expression profiling study in systemic sclerosis (SSc) to date. Dr. Jon E. Tyson (co-mentor) mentored his Master's Thesis project, investigating the clinical predictors for progression of interstitial lung disease (ILD) in SSc. The results of this large prospective study have been recently published. These productive mentor-mentee relationships will build the basis for the success of this K23 proposal. Environment: UTHSC-H is one of the largest systemic sclerosis centers in the nation. This proposal takes advantage of the infrastructure provided by the ongoing NIH-funded prospective cohort of early SSc patients, the Genetics versus ENvironment In Scleroderma Outcome Study (GENISOS-PI: Dr. Mayes) and the active Scleroderma Clinic at our institution. The candidate's adjunct appointment in the Center for Clinical Research and Evidence Based Medicine provides access to a diverse group of investigators with expertise in biostatistics, bioinformatics and epidemiology. The candidate and his mentors also have ongoing collaborations with the CCTS Core Laboratories and Clinical Research Units at the UTHSC-H. The candidate has been able to co-author 21 peer-reviewed publications (17 in the last two years) in this supportive environment. Training Plan and Career Goals: The proposed four-year program provides intensive mentoring, didactic course work and independent scientific review. The didactic curriculum complements the candidate's prior training in the Master's program with courses in genomics and proteomics, longitudinal and Bayesian data analysis, bioethics and advanced grant writing. Candidate's research efforts are focused on combining high- throughput molecular data with sophisticated epidemiology and biostatistical approaches for development of predictive biomarkers in SSc. This proposal will establish candidate's independent area of expertise with a goal of applying for NIH R01 Award, focusing on identification of predictive biomarkers in rheumatic diseases and examination of their clinical usefulness in prospective studies. Proposed Research: SSc is associated with substantial morbidity and mortality. Pulmonary involvement is the primary cause of SSc-related death. Sequential measurements of pulmonary function in patients with SSc have shown remarkable variability in the progression of ILD, ranging from an indolent course to a rapidly progressive disease leading to respiratory failure and eventually death. Although ILD is one of the most important determinants of disease in SSc, the routinely obtained demographic and clinical data are inadequate to predict the course of this devastating disease complication. Gene expression profiling with microarrays allows the simultaneous assessment of thousands of transcripts in a given tissue. Our previous studies indicate that SSc patients can be subclassified at the molecular level based on presence of an Interferon (IFN) gene expression pattern. The objective of the current proposal is to build multivariate models with gene expression profiling and serum chemokine data that will have greater predictive value for the course of ILD over the currently known parameters. We hypothesize that microarray gene expression profiling and multiplex chemokine assays will improve our currently inadequate ability to predict the course of ILD. We will identify peripheral blood cell and skin gene expression patterns that can predict the course of ILD. Then we will examine the independent predictive significance of these classifier transcripts in a multivariate model after inclusion of other known predictors. We also will investigate the interplay between immune dysregulations and fibrosis in SSc by comparison of gene expression profiles present in the concomitantly collected peripheral blood and skin samples. Several serum chemokines correlating with the IFN gene expression signature have been identified. These chemokines correlate with disease activity in other connective tissue disease. In this proposal, we will examine whether these IFN inducible chemokines also correlate with progression of SSc-ILD in the GENISOS cohort. The proposed novel translational and analytic approaches can lead to methodological advances in the field of autoimmunity and can address a significant knowledge gap in SSc clinical care and clinical trial design. Furthermore, the accompanying mentoring and course work will prepare Dr. Assassi to become an independent and productive clinician scientist and a leader in rigorously designed and conducted translational research in rheumatic diseases. PUBLIC HEALTH RELEVANCE: Interstitial lung disease is a major complication of systemic sclerosis (scleroderma) leading to increased death rates among patients with this disease. We will use advanced technology to identify molecules that predict the course of interstitial lung disease. This can lead to early detection of high risk systemic sclerosis patients who would benefit from more intensive monitoring and treatment.

描述（由申请人提供）：标题：系统性硬化症肺纤维化进展的分子标志物候选人：Assassi博士是流变学系和临床研究与循证医学中心的助理教授。他最近完成了临床研究硕士学位课程。2009年，他被选为德克萨斯大学休斯顿健康科学中心（UTHSC-H）的两位CCTS-KL 2（K12）学者之一。莫琳·D博士Mayes（主要导师）和Filemon K博士。Tan（共同导师）是他正在进行的KL 2奖的导师。在他们的指导下，这位候选人发表了迄今为止系统性硬化症（SSc）中最大的基因表达谱研究。Jon E.博士Tyson（共同导师）指导了他的硕士论文项目，调查了SSc中间质性肺病（ILD）进展的临床预测因素。这项大型前瞻性研究的结果已于近期发表。 这些富有成效的导师-学员关系将为K23提案的成功奠定基础。 环境：UTHSC-H是全国最大的系统性硬化症中心之一。该提案利用了正在进行的NIH资助的早期SSc患者前瞻性队列，遗传学与硬皮病结局研究（GENISOS-PI：Dr. Mayes）和我们机构的活跃硬皮病诊所提供的基础设施。候选人在临床研究和循证医学中心的兼职任命提供了接触具有生物统计学，生物信息学和流行病学专业知识的多样化研究人员的机会。候选人和他的导师还与UTHSC-H的CCTS核心实验室和临床研究单位进行合作。候选人已经能够共同作者21同行评审的出版物（17在过去两年中）在这种支持性的环境。 培训计划和职业目标：拟议的四年计划提供密集的指导，教学课程和独立的科学审查。教学课程补充了候选人在硕士课程中的先前培训，包括基因组学和蛋白质组学，纵向和贝叶斯数据分析，生物伦理学和高级赠款写作课程。候选人的研究工作集中在将高通量分子数据与复杂的流行病学和生物统计学方法相结合，以开发SSc的预测生物标志物。该提案将建立候选人的独立专业领域，目标是申请NIH R 01奖，重点是识别风湿性疾病的预测生物标志物，并在前瞻性研究中检查其临床有用性。 拟议研究：SSc与大量发病率和死亡率相关。肺部受累是SSC相关死亡的主要原因。SSc患者的肺功能连续测量显示ILD进展存在显著差异，从无痛病程到导致呼吸衰竭并最终死亡的快速进展性疾病。虽然ILD是SSc疾病的最重要决定因素之一，但常规获得的人口统计学和临床数据不足以预测这种毁灭性疾病并发症的病程。 基因表达谱与微阵列允许同时评估数千个转录本在一个给定的组织。我们以前的研究表明，SSc患者可以在分子水平上的干扰素（IFN）基因表达模式的基础上进行细分。 目前建议的目的是建立多变量模型与基因表达谱和血清趋化因子数据，将有更大的预测价值的ILD的过程中，目前已知的参数。我们假设微阵列基因表达谱和多重趋化因子检测将改善我们目前预测ILD病程的不足能力。 我们将确定外周血细胞和皮肤基因表达模式，可以预测ILD的过程。 然后，我们将在一个多变量模型中，包括其他已知的预测因素后，这些分类成绩单的独立预测意义。我们还将通过比较同时采集的外周血和皮肤样本中存在的基因表达谱，研究免疫失调与SSc纤维化之间的相互作用。已经鉴定了与IFN基因表达特征相关的几种血清趋化因子。这些趋化因子与其他结缔组织疾病的疾病活动相关。在本提案中，我们将研究这些IFN诱导型趋化因子是否也与GENISOS队列中的SSc-ILD进展相关。所提出的新的翻译和分析方法可以导致自身免疫领域的方法学进步，并可以解决SSc临床护理和临床试验设计中的重大知识缺口。此外，伴随的指导和课程工作将使Assassi博士成为一名独立和富有成效的临床科学家，以及在风湿性疾病中严格设计和进行转化研究的领导者。 公共卫生关系：间质性肺病是系统性硬化症（硬皮病）的主要并发症，导致患有这种疾病的患者的死亡率增加。我们将使用先进的技术来识别预测间质性肺病病程的分子。这可以导致早期发现高危系统性硬化症患者，他们将受益于更密集的监测和治疗。